- Hemispherx Affiliate Files Hepatitis C Related Notice of Invention With
the U.S. Patent Office
PHILADELPHIA--(BUSINESS WIRE)--Jan. 2, 2001--Hemispherx Biopharma, Inc.
(AMEX:HEB)(AMEX:HEBws) announced that the California Institute of
Molecular Medicine ("CIMM"), a company in which Hemispherx is the major
Corporate shareholder, has filed a Notice of Invention with the U.S.
Patent Office. This notice is titled "Replication of Human Kuppfer's
obtained from HCV infected patients by Fine Needle Biopsy Technique."
inventors describe a new method to potentially salvage critically needed
liver function without major surgery or aggressive medical intervention.
Hepatitis C is a disease of the liver caused by the Hepatitis C virus
("HCV"). Nearly four million Americans have been infected with HCV of
2.7 million are chronically affected. Chronic liver disease is apparent
70% of infected persons, with current treatment regimes being effective
only 10-40% of these people.
The proprietary CIMM approach allows the in vitro growth of hepatic
macrophages (called Kupffer's cells) from the failing liver of a patient
and reinfusion of liver cells into the same patient. This would not
the question of immunological incompatibility. CIMM also advocates a
process for maintaining and propagating Kuppfer's cells ("KC")
reproducibly in defined cell cultures using fine needle liver aspirates
from living human volunteers with potential for patients with failing
liver due to a variety of etiologies.
KCs are one of the major components of the hepatic sinusoid. These
sinusoid-lining cells actively participate in the maintenance of normal
liver function, which is critical to maintaining life itself.
Deterioration of KCs is implicated in the pathogenesis of both alcoholic
liver disease and of chronically infected HCV patients.
Alcoholic hepatitis often leads to cirrhosis where normal liver cells
damaged and replaced by scar tissue. This is a major problem and
burden to America, since over 25 million Americans are afflicted with
liver and gallbladder diseases. Each year more the 25,000 die from
liver disease and cirrhosis. The only effective present treatment for
life threatening liver diseases leading to organ failure is liver
The potential market for the KC maintenance and propagation techniques
will be the 14,000 people in the U.S. actively seeking a liver
Additional thousands are progressing towards a failing liver and will
need transplantation or a successful alternative method to restore
function. Several hundred thousand who have alcoholic cirrhosis may also
benefit from the proprietary process. Medical costs of a liver
are approximately $300,000 and are far beyond the financial reserves of
Commenting on the development, Dr. William A. Carter, CEO of Hemispherx
Biopharma, stated: "Hepatitis C is a progressive insidious disease of
liver for which the majority of sufferers have no cure. Many hospitals
refuse even to offer liver transplants to alcoholics. This proprietary
propagation method for Kuppfer's cells may offer HCV sufferers and
alcoholics with significant liver damage, a chance to substantially
prolong their normal liver functions."
Similar proprietary concepts, which do not involve specific new drug
applications, have been successfully used by others to treat certain
malignancies especially involving bone marrow.
Zaki Salahuddin is a preeminent researcher in virology/molecular
He is the author of over 100 scientific papers and holds several dozen
patents. Zaki Salahuddin worked at the National Institutes of Health
("NIH") for many years and is very well known for his published work in
the field of retro-virology (HTLV, HIV), cytokines and the discovery of
human herpesvirus type-6 (HHV-6).
Information contained in this news release other than historical
information including the referenced Notice of Invention should be
considered forward-looking and is subject to various risk factors and
uncertainties. For instance, the strategies and operations of HEMISPHERX
involve risks of competition, changing market conditions, changes in
and regulations affecting these industries and numerous other factors
discussed in this release and in the Company's filings with the
and Exchange Commission. Accordingly, actual results may differ
from those in any forward-looking statements. The Company disclaims any
obligation to update the forward-looking statements.
Hemispherx Biopharma, Inc.
William A. Carter, 215/988-0080
Dianne Will, 214/954-9300
Mark Kollar, 212/232-2222
HEB's Web Site: www.hemispherx.com
- Hepatology Focus
Update on Hepatitis C Treatment
Series Editor: Paul Martin, MD, Cedars-Sinai Medical Center, and UCLA
Medicine, Los Angeles, California
Sammy Saab, MD, Clinical Instructor, UCLA School of Medicine, Los
Angeles, California, and
Paul Martin, MD, Medical Director, Liver Transplantation, Cedars-Sinai
Associate Professor of Medicine, UCLA School of Medicine, Los Angeles,
[Medscape Gastroenterology 3(1), 2001. © 2001 Medscape, Inc.]
Although screening of blood products and other interventions such as
programs have significantly reduced the incidence of acute hepatitis C
in the United States and
elsewhere, there remains a large reservoir of chronically infected
individuals, many of whom are
unaware of their infection. Current estimates suggest a seroprevalence
of 1.8% among Americans,
most of whom are viremic. The clinical burden of chronic hepatitis C
virus (HCV) infection is
expected to increase over the next 2-3 decades as a large cohort of
patients infected between the
1960s and 1980s, primarily as a result of recreational drug use,
develops progressive liver disease.
Between 8000 and 10,000 deaths each year in the United States are
believed to be caused by
infection with HCV -- which is now the most frequent indication for
Even before identification of HCV, interferon-alfa (IFN-alfa) had been
evaluated as a potential
therapy for what had been called chronic non-A, non-B hepatitis.
Further studies using normalization of serum alanine aminotransferase
(ALT) levels and
improvement in liver histology as endpoints demonstrated the efficacy of
IFN-alfa as therapy for
the causative agent of chronic non-A, non-B hepatitis (HCV).[4,5]
Subsequent advances in
molecular diagnosis have now increasingly allowed establishment of
virologic criteria to evaluate
efficacy of treatment in patients with chronic hepatitis C (see Table).
Definition of Virologic Response in Patients Receiving Therapy for
Chronic Hepatitis C
End-of-treatment response (ETR) refers to absence of viremia (ie, serum
HCV RNA below level
of detection) at completion of therapy. Sustained response (SR)
indicates persistent absence of
serum HCV RNA 6 months or more after cessation of therapy. A study by
coworkers on the long-term clinical outcome in 80 patients with
chronic HCV followed for a
mean of 4 years following therapy highlighted the clinical implications
of a virologic SR. Persistent
absence of HCV RNA from serum was observed in 96% of patients with a
lack of histologic
progression on serial liver biopsy. In addition, ALT levels were
persistently normal in over 90%.
The most recent follow-up biopsy showed normal or near normal histologic
findings in 62% of
these patients. Thus, virologic SR was shown to be associated with both
an absence of detectable
serum HCV RNA and marked histologic improvement.
Relapsers are defined as patients who have undetectable serum HCV RNA at
therapy but who subsequently redevelop viremia. Nonresponders (NRs) are
patients who fail to
clear HCV RNA from serum during therapy.
A recent paper by Everson and associates underscores the importance
of HCV RNA testing in
defining treatment response. In patients with marked fibrosis and
cirrhosis, they found a major
discrepancy between biochemical (ALT) and virologic (HCV RNA) responses
to therapy. Two of
7 (29%) patients with marked fibrosis and 2 of 6 (33%) patients with
cirrhosis cleared HCV RNA
without normalizing ALT. In contrast, only 3 patients (10%) without
significant fibrosis had an
HCV RNA response without normalization of ALT. Thus, clinical trials for
chronic HCV are now
typically reported using virologic response rates.
What then are the current goals of antiviral therapy in patients with
chronic hepatitis C? Immediate
goals are eradication of viral replication and improvement in hepatic
inflammation and fibrosis.
Long-term potential goals include prevention of cirrhosis,
hepatocellular carcinoma, and liver
IFN-alfa 2 was the first agent approved for the treatment of chronic
HCV. Since the initial trials
establishing its efficacy, data regarding treatment duration and dose
have evolved. Currently, 2
forms of IFN-alfa that differ by a single amino acid residue are
approved for treatment of chronic
HCV infection: IFN-alfa 2b (Schering-Plough, Kenilworth, New Jersey) and
(Hoffmann-La Roche, Basel, Switzerland). The recommended dose is 3
million units 3 times each
week for up to 12 months.
When used alone in monotherapy, the alfa interferons have similar
efficacies, with SRs of only 10%
to 20%, with the modestly higher response rates associated with more
Higher-dose IFN-alfa (ie, > 9 million units per week) results in SRs
between 8% and 20% in
treatment-naive patients. High-dose IFN-alfa has also been studied in
NRs and relapsers, but with
mixed results. With prior NR, SRs achieved with higher doses are only
between 0% and 4%. In
relapsers, SRs range from 20% to 40%. However, side effects are more
troublesome with higher
Because of the low overall response rate to standard IFN-alfa, more
recent studies have focused
on newer regimens, including synthetic IFN (IFN alfacon-1),
"combination" therapy (IFN-alfa 2b
+ ribavirin), and longer-acting IFNs (pegylated IFNs). A number of major
of NR have been identified, notably HCV genotype 1, the presence of
cirrhosis, and higher viral
load. In addition, patient's race appears to affect response to IFN,
with African Americans
having an overall low SR to therapy.
A significant improvement in SR resulted from the addition of ribavirin
to standard IFN-alfa.
Ribavirin, a guanosine analogue, was initially evaluated as monotherapy
for chronic HCV because
of its antiviral activity against other RNA viruses.[11-13] Although as
monotherapy it reduces ALT
levels, it does not appear to have a direct antiviral effect and fails
to lower serum HCV RNA
levels. Moreover, results of most studies with ribavirin have found no
improvement in hepatic
histology, although a longer 2-year treatment regimen was shown to
However, in combination with IFN-alfa 2b, ribavirin leads to a
significant increase in SR in
treatment-naive patients. SRs of 31% with 24 weeks and 38% with 48
weeks of combination
therapy were achieved vs 6% with 24 weeks and 13% with 48 weeks of IFN
relapsers, enhanced SR rates also occur on retreatment using combination
therapy, from 30% to
49%; in prior NRs, SR of 14% has been reported with 6 months of
Histologic improvement was more common among treatment-naive patients
combination therapy. Similar improvement was found in a randomized
controlled trial of
However, the improved SR rates observed with combination therapy are
also associated with
more expense and an increased frequency of adverse effects compared with
monotherapy. Dose-related hemolytic anemia is a particular concern
with ribavirin[11,13] as is
teratogenicity, based on animal studies. The mean drop in hemoglobin
in patients treated with
combination therapy is between 2 and 3 g/dL, although a fall of more
than 4 g/dL has been
observed in about 10% of patients. The anemia may be poorly tolerated in
patients with ischemic
heart disease in particular as treatment is extended to older
patients. Accumulation of ribavirin
metabolites that are not cleared by dialysis occurs in end-stage renal
Consensus IFN (CIFN; IFN alfacon-1, Amgen, Thousand Oaks, California) is
engineered compound synthesized by combining the most common amino acid
naturally occurring IFNs.[19,20] CIFN shares 88% homology with IFN-alfa
and 30% with
IFN-beta. Although it has greater cytokine induction, antiviral,
antiproliferative, natural killer cell,
and gene-induction activities than both IFN-alfa 2a and IFN-alfa 2b on
an equal mass basis, initial
studies with the recommended CIFN dose of 9 mcg in IFN-naive patients
with chronic hepatitis C
resulted in viral response rates similar to those achieved with standard
More recently, higher-dosage CIFN regimens of 15 mcg thrice weekly were
reported to result in
virologic SRs of 13% in prior NRs and 58% in relapsers treated for 48
Pharmacokinetic studies have provided a rationale for enhanced IFN
dosing. The initial decline in
serum HCV RNA levels seen after a single dose of IFN therapy is believed
to reflect a direct
antiviral effect, whereas the subsequent and more delayed decline in HCV
RNA levels is due to
destruction of infected hepatocytes. An important limitation of the
antiviral effect of standard
IFN dosing is the rapid decline in circulating drug level with
thrice-weekly administration. The short
half-life of the drug and the rapid production of HCV virions diminish
the efficacy of standard IFN
therapy. In an effort to achieve more stable and efficacious IFN
activity, pegylated formulations
have been developed.
The production of a pegylated IFN involves the addition of a nontoxic
long-acting formulation of
interferon using the drug delivery system of pegylation. Polyethylene
glycol molecules are added to
IFN-alfa 2a (Pegasys, Hoffmann-La Roche) and IFN-alfa 2b (PEG-Intron,
Pegylation is already used in the delivery of other drugs. Its
attachment to IFN-alfa permits
In a recent report, Zeuzem and colleagues indicate that at week 72,
the SR was 39% after 48
weeks of therapy at a dose of 180 mcg with pegylated IFN alfa-2a
compared with a 19% SR in
control patients. Drug discontinuation in these treatment-naive patients
and frequency of dose
reduction were similar in the 2 treatment arms. Heathcote and
colleagues have also reported on
the use of pegylated IFN alfa-2a in a controlled trial in cirrhotic
patients. SR was 30% following 48
weeks of therapy with 180 mcg, compared with 8% for patients treated
with standard alfa IFN,
again without a significant increase in side effects with the pegylated
Trepo and colleagues have also reported, in abstract form, initial
studies with pegylated IFN-alfa
2b. Virologic SR for the unmodified IFN-alfa 2b (3 million units, thrice
weekly for 48 weeks) was
12%, whereas the SR for the pegylated IFN-alfa 2b was 18%, 25%, and 23%
with 0.5 mcg/kg,
1.0 mcg/kg, and 1.5 mcg/kg, respectively, administered weekly in
As with standard IFN-alfa monotherapy, ribavirin may augment response
rates when combined
with the pegylated IFNs.[26,27] Recent trials will help evaluate further
the role of ribavirin in
augmenting the efficacy of pegylated IFN (see Figure).
Figure. Initial antiviral therapy against hepatitis C virus.*
* Abbreviations: IFN = interferon; CSN = consensus interferon;
interferon + ribavirin; PEG = pegylated interferon; PEG/RIB =
pegylated interferon +
There has been continued interest in developing non-IFN-based therapies
for HCV despite the
promise of the pegylated IFNs. A recent study examined the role of human
treating prior NRs with chronic HCV. Although, HCV RNA remained
detectable in all patients
at the end of treatment, 5 (23%) of the 22 treated patients had
persistent ALT normalization at
the end of follow-up. Future studies should determine whether combining
interleukin-10 with other
antiviral agents will increase efficacy in this setting. Interleukin-12
has also been evaluated as
monotherapy, again without clear antiviral benefit.
There is also increasing enthusiasm for targeting HCV molecular
products. For example, ribozyme
gene therapy has the potential to accurately degrade HCV RNA. Human
studies are anticipated.
Treatment options for HCV infection continue to expand. Whereas SRs of
10% were achieved
with IFN monotherapy only several years ago, it may soon be possible to
achieve SR rates greater
than 50% with combination pegylated IFN and ribavirin. Molecular-based,
strategies are also likely to become a reality in the future, although
therapy will remain
interferon-based the next several years.
Table. Response (HCV RNA/ALT*) to Antiviral Therapy
Type of Response
6 Months After
* HCV RNA measured by polymerase chain reaction; ALT = alanine
aminotransferase; HCV = hepatitis C virus.
Positive denotes HCV RNA present in the serum by polymerase chain
abnormal alanine aminotransferase values. Negative denotes no serum
HCV RNA by
polymerase chain reaction and normal alanine aminotransferase
1.Alter MJ, Kruszon-Moran D, Nainan OV, et al. The prevalence of
hepatitis C virus
infection in the United States, 1988 through 1994. N Engl J Med.
2.Centers for Disease Control and Prevention Web site. Available at
Accessed February 1, 2000.
3.Hoofnagle JH, Mullen KD, Jones DB, et al. Treatment of chronic
non-A, non-B hepatitis
with recombinant human alpha interferon. A preliminary report. N
Engl J Med.
4.Di Bisceglie AM, Martin P, Kassianides C, et al. Recombinant
interferon alfa therapy for
chronic hepatitis C. A randomized, double-blind, placebo-controlled
trial. N Engl J Med.
5.Davis GL, Balart LA, Schiff ER, et al. Treatment of chronic
hepatitis C with recombinant
interferon alfa. A multicenter randomized, controlled trial.
Hepatitis Interventional Therapy
Group. N Engl J Med. 1989;321:1501-1506.
6.Marcellin P, Boyer N, Gervais A, et al. Long-term histologic
improvement and loss of
detectable intrahepatic HCV RNA in patients with chronic hepatitis
C and sustained
response to interferon-alpha therapy. Ann Intern Med.
7.Everson GT, Jensen DM, Craig JR, et al. Efficacy of interferon
treatment for patients with
chronic hepatitis C: comparison of response in cirrhotics,
fibrotics, or nonfibrotics.
8.Iino S. High dose interferon treatment in chronic hepatitis C. Gut.
9.Davis GL, Lau JY. Factors predictive of a beneficial response to
therapy of hepatitis C.
10.Reddy KR, Hoofnagle JH, Tong MJ, et al. Racial differences in
responses to therapy with
interferon in chronic hepatitis C. Consensus Interferon Study
11.Dusheiko G, Main J, Thomas H, et al. Ribavirin treatment for
patients with chronic hepatitis
C: results of a placebo-controlled study. J Hepatol.
12.Bodenheimer HC Jr, Lindsay KL, Davis GL, et al. Tolerance and
efficacy of oral ribavirin
treatment of chronic hepatitis C: a multicenter trial. Hepatology.
13.Di Bisceglie AM, Conjeevaram HS, Fried MW, et al. Ribavirin as
therapy for chronic
hepatitis C. A randomized, double-blind, placebo-controlled trial.
Ann Intern Med.
14.McHutchison JG, Gordon SC, Schiff ER, et al. Interferon alfa-2b
alone or in combination
with ribavirin as initial treatment for chronic hepatitis C.
Hepatitis Interventional Therapy
Group. N Engl J Med. 1998;339:1485-1492.
15.Davis GL, Esteban-Mur R, Rustgi V, et al. Interferon alfa-2b alone
or in combination with
ribavirin for the treatment of relapse of chronic hepatitis C.
Interventional Therapy Group. N Engl J Med. 1998;339:1493-1499.
16.Barbaro G, Di Lorenzo G, Belloni G, et al. Interferon alpha-2B and
ribavirin in combination
for patients with chronic hepatitis C who failed to respond to, or
relapsed after, interferon
alpha therapy: a randomized trial. Am J Med. 1999;107:112-118.
17.Lyons M, Coddou A, Varon C, et al. Side effect profile of
combination with interferon
alpha-2b and ribavirin in a community-based clinical trial.
18.Glue P, Tan Y, Sacks M, et al. Use of ribavirin in patients with
renal and hepatic dysfunction
-- pharmacokinetic data and recommendations. Hepatology.
19.Ozes ON, Reiter Z, Klein S, et al. A comparison of interferon-Con1
recombinant interferons-alpha: antiviral, antiproliferative, and
natural killer-inducing activities.
J Interferon Res. 1992;12:55-59.
20.Klein SB, Blatt LM, Taylor MW. Consensus interferon induces peak
at lower concentrations than interferon-alpha 2a. J Interferon Res.
21.Heathcote EJ, Keeffe EB, Lee SS, et al. Re-treatment of chronic
hepatitis C with consensus
interferon. Hepatology. 1998;27:1136-1143.
22.Zeuzem S. Clinical implications of hepatitis C viral kinetics. J
23.Zeuzem S, Feinman SV, Raseneck J, et al. Peginterferon alfa-2a in
patients with chronic
hepatitis C. N Engl J Med. 2000;343:1666-1672.
24.Heathcote EJ, Shiffman ML, Cooksley WG, et al. Peginterferon
alfa-2a in patients with
chronic hepatitis C and cirrhosis. N Engl J Med.
25.Trepo C, Lindsay K, Niederau C, et al. Pegylated interferon alfa-2B
monotherapy is superior to interferon alfa-2B (Intron A) for the
treatment of chronic
hepatitis C. J Hepatol. 2000;32:29.
26.Sulkowski MS, Reindollar R, Yu J. Pegylated interferon alfa-2A
(PEGASYS) and ribavirin
combination therapy for chronic hepatitis C: a phase II open-label
27.Manns MP, McHutchinson JG, Gordan S, et al. Peginterferon alfa-2b
compared to interferon alfa-2b plus ribavirin for the treatment of
chronic hepatitis C: 24
week treatment analysis of a multicenter, multinational phase III
randomized controlled trial.
28.Nelson DR, Lauwers GY, Lau JY, et al. Interleukin 10 treatment
reduces fibrosis in patients
with chronic hepatitis C: a pilot trial of interferon
29.Zeuzem S, Hopf U, Carreno V, et al. A phase I/II study of
interleukin-12 in patients with chronic hepatitis C. Hepatology.
30.Welch PJ, Yei S, Barber JR. Ribozyme gene therapy for hepatitis C
virus infection. Clin
Diagn Virol. 1998;10:163-171.